Total addressable market in the US is US$70Bn
§ Meeting with FDA provided Echo IQ with a clear path to gain regulatory clearance for EchoSolv HF
§ Agreement includes potential for licencing of EchoSolv HF to 30 Mayo Clinic Care Network sites using the group’s proprietary integration software system for a three-year period
§ Validation study expected to commence this quarter with FDA clearance anticipated H2 CY2025
Developments follow two completed studies using EchoSolv HF which demonstrated:
o EIQ’s AI standalone performance detected 86% of heartfailure cases (vs 46% detection in standard clinical practice)
o AI and clinical evaluation combined increased accuracyto 97% in high-risk individuals
…..not to mention the phenomenal increase in efficiencycutting diagnosis from days to hours…
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.015(6.67%) |
Mkt cap ! $135.4M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 20.5¢ | $1.084M | 5.068M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 99174 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 38542 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| EIQ (ASX) Chart |